What is tucatinib? What kind of targeted therapy drug does it belong to?

Tucatinib (Tucatinib) is a targeted drug that is a tyrosine kinase inhibitor (TKI). It is specifically used to treat HER2-positive breast cancer, especially in patients who have not responded well to other treatments or have metastasized. HER2 (human epidermal growth factor receptor 2) is a protein involved in the growth and division of cancer cells. In some breast cancer patients, HER2 is overexpressed or mutated, leading to malignant proliferation of tumors. Tucatinib inhibits the signaling of HER2 receptors, preventing the proliferation of tumor cells and achieving the effect of inhibiting tumor growth.

Tucatinib is a highly selective HER2 receptor inhibitor with greater specificity than other HER2 targeted drugs, such as trastuzumab. It can penetrate the blood-brain barrier and has a good therapeutic effect on HER2-positive breast cancer with brain metastasis. HER2Patients with positive breast cancer often develop brain metastases, and other commonly used drugs may have difficulty crossing the blood-brain barrier effectively. Therefore, the unique advantage of tucatinib lies in its therapeutic effect on brain metastases. This makes tucatinib an important drug for the treatment of advanced or metastatic HER2-positive breast cancer.

In addition, the tucatinib combination treatment regimen has also achieved significant clinical efficacy. It is often used in combination with other anti-cancer drugs, such as trastuzumab and chemotherapy drugs, to significantly increase the effectiveness of treatment. In the treatment of HER2 positive breast cancer, single drug therapy is often difficult to achieve the best effect, so combination therapy has become an effective treatment strategy. Studies of the combination of tucatinib and trastuzumab have shown that this combination can effectively prolong progression-free survival and improve overall survival.

Although tucatinib has shown good efficacy in the treatment ofHER2 positive breast cancer, it may also cause some side effects. Common adverse reactions include diarrhea, fatigue, loss of appetite, nausea, etc. However, these side effects can usually be alleviated with appropriate management and symptomatic treatment. Patients need to undergo regular physical examinations when using tucatinib to ensure the safety of the drug, and adjust the treatment plan according to the doctor's guidance to achieve the best therapeutic effect.

Reference materials:https://www.tukysa.com/